永勝醫療(01612.HK)料年度淨利降65%
格隆匯2月14日丨永勝醫療(01612.HK)公告,預期集團於2019財政年度公司擁有人應占溢利將較截至2018年12月31日止年度減少約2000萬港元或65%。儘管集團總收益增加1420萬港元或2.9%,董事會認為,預期溢利減少主要歸因於以下因素的綜合影響:
(i)於2019財政年度並無其他應付款項一次性撥回;(ii)銷售及分銷開支增加440萬港元或15.9%,主要由於客户對高規格交付服務的需求增加及新產品的市場推廣開支增加;(iii)行政開支增加1280萬港元或14.3%,主要由於增加研究及開發開支以推進集團在研產品組合研發工作以及支援新推出的英仕醫療產品、銷售及研發辦事處遷至東莞松山湖科技產業園以及平均工資和人員總數普遍上升;及(iv)根據初步評估,2019財政年度的商譽及投資減值虧損約為10百萬港元,此方面最終金額有待進一步評估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.